DexCom (DXCM)

• Market cap: $32.1B
• 1 day: -1.04%
• 5 days: -5.66%
• 1 month: -2.52%
• 3 months: 19.73%
• 6 months: 6.22%
• Year to date: 4.45%
• 1 year: -27.96%
• 5 years: -17.76%
• 10 years: 353.23%
• Sector: Healthcare
• Industry: Medical Devices

About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Employees: 10,300

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

21% more repeat investments, than reductions

Existing positions increased: 367 | Existing positions reduced: 303

19% more call options, than puts

Call options by funds: $401M | Put options by funds: $337M

0.05% more ownership

Funds ownership: 91.2% [Q4 2024] → 91.25% (+0.05%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]

4% less first-time investments, than exits

New positions opened: 108 | Existing positions closed: 113

2% less funds holding

Funds holding: 931 [Q4 2024] → 909 (-22) [Q1 2025]

12% less capital invested

Capital invested by funds: $27.7B [Q4 2024] → $24.3B (-$3.42B) [Q1 2025]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $85 4% upside
• Avg. target: $98 19% upside
• High target: $106 29% upside

7 analyst ratings

• positive: 6 86%
• neutral: 1 14%
• negative: 0 0%

Goldman Sachs Kate McShane	27% upside $104	Buy Initiated	30 May 2025
Citigroup Joanne Wuensch	24% upside $102	Buy Maintained	22 May 2025
Barclays Matt Miksic	13% upside $93	Equal-Weight Maintained	5 May 2025
Canaccord Genuity William Plovanic	29% upside $106	Buy Maintained	2 May 2025
Piper Sandler Matt O'Brien	10% upside $90	Overweight Maintained	2 May 2025